A5001246578- Growth Hormone and Insulin-like Growth Factors
- Protein purification and stability
- Monoclonal and Polyclonal Antibodies Research
- Estrogen and related hormone effects
- Neurogenesis and neuroplasticity mechanisms
- Neuroscience and Neuropharmacology Research
- Nuclear Receptors and Signaling
- Cancer, Hypoxia, and Metabolism
- Viral Infectious Diseases and Gene Expression in Insects
- Fungal and yeast genetics research
- Spaceflight effects on biology
- Alzheimer's disease research and treatments
- Muscle Physiology and Disorders
- Sirtuins and Resveratrol in Medicine
- Retinoids in leukemia and cellular processes
- TGF-β signaling in diseases
- Enzyme Structure and Function
- Bone health and osteoporosis research
- Lipid metabolism and biosynthesis
- Vitamin D Research Studies
- Heat shock proteins research
- Bone Metabolism and Diseases
- thermodynamics and calorimetric analyses
- Microbial Metabolic Engineering and Bioproduction
- Bone health and treatments
Icahn School of Medicine at Mount Sinai
2022-2024
The Mount
2022-2023
National Institute of Pharmaceutical Education and Research
2017-2022
The past decade has seen significant advances in our understanding of skeletal homeostasis and the mechanisms that mediate loss bone integrity disease. Recent breakthroughs have arisen mainly from identifying disease-causing mutations modeling human disease rodents, essence, highlighting integrative nature physiology. It become increasingly clear cells, osteoblasts, osteoclasts, osteocytes, communicate regulate fate each other through RANK/RANKL/OPG, liver X receptors (LXRs), EphirinB2-EphB4...
Pharmacological and genetic studies over the past decade have established follicle-stimulating hormone (FSH) as an actionable target for diseases affecting millions, namely osteoporosis, obesity, Alzheimer's disease. Blocking FSH action prevents bone loss, fat gain, neurodegeneration in mice. We recently developed a first-in-class, humanized, epitope-specific FSH-blocking antibody, MS-Hu6, with K
Highly concentrated antibody formulations are oftentimes required for subcutaneous, self-administered biologics. Here, we report the development of a unique formulation our first-in-class FSH-blocking humanized antibody, MS-Hu6, which propose to move clinic osteoporosis, obesity, and Alzheimer's disease. The studies were carried out using Good Laboratory Practice (GLP) platform, compliant with Code Federal Regulations (Title 21, Part 58). We first used protein thermal shift, size exclusion...
<title>Abstract</title> Alzheimer’s disease (AD) is a major progressive neurodegenerative disorder of the aging population. High post–menopausal levels pituitary gonadotropin follicle–stimulating hormone (FSH) are strongly associated with onset AD, and we have shown recently that FSH directly activates hippocampal <italic>Fshr</italic> to drive AD–like pathology memory loss in mice. To establish role for loss, used female <italic>3xTg;Fshr</italic><sup>+/+</sup>,...
Abstract Biopharmaceutical products are formulated using several Food and Drug Administration (FDA) approved excipients within the inactive ingredient limit to maintain their storage stability shelf life. Here, we have screened optimized different sets of excipient combinations yield a thermally stable formulation for humanized follicle‐stimulating hormone (FSH)–blocking antibody, MS‐Hu6. We used protein thermal shift assay in which rising temperatures resulted maximal unfolding at melting...
Proteolytic cleavage of huntingtin gives rise to N-terminal fragments. While the role truncated mutant is described in Huntington's disease (HD) pathogenesis, function wild-type protein less studied. The yeast model HD generated by presence FLAG tag and absence polyproline tract as flanking sequences elongated polyglutamine stretch. We show that same sequence derived from exon1 able inhibit aggregation proteins vitro cells. It stabilize client varied luciferase, α-synuclein, p53 a soluble...
Abstract Glycerol 3‐phosphate dehydrogenase (Gpd1 isoform) catalyzes the rate limiting step of glycerol synthesis and is a critical component osmo‐responsive machinery in yeast. The three‐dimensional structure enzyme similar to from many other organisms, including humans. A recent study with human has proposed K120 (K152 yeast) be correct orientation for catalysis; K204 (K245 out plane not participant catalytic cycle. current work was carried establish role K245 cycle yeast Gpd1. K245A...
ABSTRACT Alzheimer’s disease (AD) is a major progressive neurodegenerative disorder of the aging population. High post–menopausal levels pituitary gonadotropin follicle–stimulating hormone (FSH) are strongly associated with onset AD, and we have shown recently that FSH directly activates hippocampal Fshr to drive AD–like pathology memory loss in mice. To establish role for loss, used female 3xTg;Fshr +/+ , +/– -/- mice were either left unoperated or underwent sham surgery ovariectomy at 8...
Abstract Disclosure: F. Sultana: None. M.L. Temple: S. Kim: V. Ryu: Korkmaz: A. Gumerova: P. Georgii: U. Cheliadinova: D. Vasilyeva: Laurencin: R. Witztum: O. Barak: L. Cullen: A.R. Pallapati: Rojekar: J. Gimenez Roig: Lizneva: W. Zhou: T. Yuen: M. Zaidi: Severe osteoporosis and bone fractures are strongly associated with long-term or recurring glucocorticoid use in people. Steroids have traditionally been used as an anti-inflammatory immunosuppressive agent, while their has widely...
Abstract Disclosure: S. Sims: None. F. Sen: Sultana: A. Liu: V. Laurencin: Gumerova: O. Barak: Rojekar: A.R. Pallapati: L. Cullen: R. Chen: K. Goosens: Ryu: T. Yuen: M. Zaidi: Frolinger: Korkmaz: Alzheimer’s disease (AD) is a major progressive neurodegenerative disorder of the aging population, accounting for more than 60-80% dementia cases. High serum level pituitary gonadotropin, follicle-stimulating hormone (FSH), strongly associated with onset AD. We recently showed that FSH activates...
ABSTRACT Highly concentrated antibody formulations are oftentimes required for subcutaneous, self-administered biologics. Here, we report the creation of a unique formulation our first–in– class FSH–blocking humanized antibody, MS-Hu6, which propose to move clinic osteoporosis, obesity, and Alzheimer’s disease. The studies were carried out using Good Laboratory Practice (GLP) platform, compliant with Code Federal Regulations (Title 21, Part 58). We first used protein thermal shift, size...
Abstract Disclosure: D. Lizneva: None. A. Gumerova: K. Ievleva: O. Barak: F. Korkmaz: J. Gimenez Roig: T. Frolinger: G. Pevnev: Sultana: N. Kramskiy: S. Wizman: M. Orloff: A.R. Pallapati: Rojekar: V. Ryu: Moldavski: Yuen: Zaidi: We provide compelling evidence that LH is a pro–lean hormone, and ORG43553, the first low-molecular-weight agonist of luteinizing hormone receptor (LHCGR) induces leanness promotes energy expenditure in mice. detected Lhcgr transcripts white adipose tissue (WAT)...
Abstract Disclosure: A.R. Pallapati: None. J. Gimenez-Roig: S. Rojekar: F. Korkmaz: D. Sant: O. Barak: Sultana: Moldavski: A. Gumerova: H.S. Kannangara: U. Cheliadinova: C.J. Rosen: J.N. Caminis: M. Meseck: V.E. Demambro: S.L. Sims: Gera: R. Witztum: Miyashita: V. Ryu: Saxena: T. Frolinger: Macdonald: Kim: G. Pevnev: Lizneva: Yuen: Zaidi: Pharmacological and genetic studies suggest that FSH is an actionable target for diseases affecting millions, notably osteoporosis, obesity Alzheimer’s...
Abstract Disclosure: S. Rojekar: None. A.R. Pallapati: J. Gimenez–Roig: D. Sant: Gera: F. Korkmaz: Sultana: O. Barak: Moldavski: U. Cheliadinova: A. Gumerova: Miyashita: H.S. Kannangara: T. Frolinger: R. Witztum: Macdonald: P. Georgii: S.L. Sims: J.N. Caminis: M. Meseck: V. Ryu: Kim: Lizneva: Yuen: Zaidi: Highly concentrated antibody formulations are oftentimes required for subcutaneous, self-administered biologics. Here, we report the creation of a unique formulation our first-in-class...